Table 5.

Associations of Use of Nonsteroidal Antiinflammatory Drugs^a With Risk of Benign Prostatic Hyperplasia, According to Indications for NSAID Use, Prostate Cancer Prevention Trial, 1993–2003^b

	Indication for NSAID Use
	None (n = 2,630)			Inflammatory Conditions Only (n = 429)			Noninflammatory Conditions Only (n = 546)			Neurologic Conditions Only (n = 434)
	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI
Total	229			52			46			43
Any NSAID use	112	1.06	0.82, 1.38	37	1.79	0.98, 3.27	34	1.82	0.94, 3.52	26	1.31	0.71, 2.42
Aspirin use	104	1.10	0.85, 1.43	30	1.73	1.00, 3.01	31	2.10	1.13, 3.89	23	1.34	0.73, 2.44
Nonaspirin NSAID use	17	0.88	0.54, 1.44	17	1.54	0.86, 2.75	16	1.80	0.98, 3.31	7	1.13	0.50, 2.55
	Indication for NSAID Use
	Inflammatory and Noninflammatory Conditions (n = 273)			Noninflammatory and Neurologic Conditions (n = 162)			Inflammatory and Neurologic Conditions (n = 130)			All Indications (n = 131)
	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI	No. of Cases	HR	95% CI
Total	40			16			28			17
Any NSAID use	26	0.91	0.47, 1.74	9	0.69	0.26, 1.86	18	1.18	0.55, 2.57	13	1.81	0.60, 5.66
Aspirin use	16	0.64	0.24, 1.20	8	0.88	0.33, 2.34	16	1.34	0.63, 2.83	8	1.24	0.48, 3.21
Nonaspirin NSAID use	17	1.63	0.87, 3.07	5	1.16	0.40, 3.35	7	1.07	0.46, 2.54	10	2.20	0. 83, 5.81

Abbreviations: BPH, benign prostatic hyperplasia; CI, confidence interval; HR, hazard ratio; NSAID, nonsteroidal antiinflammatory drug.

^a A first report of medication use within 6 months of a BPH or censoring event was not considered exposure.

^b Results were adjusted for age, race/ethnicity, and body mass index.